![](/img/cover-not-exists.png)
68. Randomized trial between the selective aromatase inhibitor formestane (Lentaron) or tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: confirmation of bioequivalence in survival
C.M. Royce, L. Mauriac, R. Pérez Carrion, V. Alberola, F. Calabresi, R.Th. Michel, R. Santos, E. WehrleVolume:
4
Year:
1995
Language:
english
DOI:
10.1016/0960-9776(95)90160-4
File:
PDF, 148 KB
english, 1995